Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.21M | -1.67M | -1.82M | -1.82M | -2.21M |
| Total Depreciation and Amortization | 20.70K | 20.40K | 22.00K | 21.80K | 21.60K |
| Total Amortization of Deferred Charges | 240.70K | 262.80K | 281.50K | 294.00K | 311.50K |
| Total Other Non-Cash Items | 53.92M | 244.90K | 293.90K | 152.30K | 509.70K |
| Change in Net Operating Assets | 393.00K | 537.10K | 389.40K | 417.50K | 514.30K |
| Cash from Operations | -638.00K | -604.60K | -837.20K | -935.20K | -853.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 828.40K | 688.50K | 784.20K | 1.06M | 822.80K |
| Total Debt Repaid | -106.40K | -98.40K | 0.00 | -142.90K | -142.90K |
| Issuance of Common Stock | 12.00K | 23.10K | 23.10K | 23.10K | 111.10K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 734.00K | 613.10K | 807.20K | 941.80K | 790.80K |
| Foreign Exchange rate Adjustments | -51.50K | -65.60K | 32.60K | 4.30K | -24.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.60K | -56.90K | 2.70K | 11.10K | -87.00K |